Incyte (INCY) Q3 2026 Earnings
Includes a one-time $1.23 billion IPR&D expense related to the acquisition of Vega Therapeutics (included in both GAAP and non-GAAP R&D); GAAP diluted EPS was $(3.86).
How Did INCY Stock React to Q3 2026 Earnings?
Did INCY Beat Earnings? Q3 2026 Results
Yes. Incyte reported Q3 2026 earnings of $-3.60 a share on Oct 29, 2026, beating the $-3.84 consensus estimate by 6.1%. Revenue was $1.6B against a $1.5B estimate.
Incyte Corporation posted a stronger-than-expected third quarter of fiscal 2026, beating Wall Street on both the top and bottom lines despite absorbing a substantial acquisition charge that drove a wide net loss. Revenue climbed 14.0% year over year to $1.56 billion, ahead of the $1.48 billion consensus by 5.55%, while adjusted non-GAAP EPS came in at a loss of $3.60, beating the $3.84 consensus estimate by 6.14%. The headline loss reflected a $1.23 billion in-process research and development charge tied to Incyte's July acquisition of Vega Therapeutics, which brought the Phase 3 latarcibart program for von Willebrand disease into the pipeline. Underneath that charge, commercial momentum was broad-based, with Opzelura growing 36% and the Hematology and Oncology portfolio advancing 38%, led by triple-digit growth in Zynyz. Incyte raised its full-year total net sales guidance to $5.21 billion to $5.30 billion and lifted its Opzelura outlook to $1.10 billion to $1.12 billion, with investors also watching promising ESMO data for INCB161734 in pancreatic cancer as a key longer-term growth driver.
- Jakafi growth driven by a 12% increase in paid demand and growth across all indications
- Opzelura growth driven by increased patient demand in atopic dermatitis and vitiligo and improved net pricing following the line extension settlement
- Hematology and Oncology growth driven by increased demand for Niktimvo, Zynyz and Monjuvi/Minjuvi
- $1.23 billion one-time IPR&D expense from the Vega acquisition drove the operating and net loss
- SG&A increase primarily due to pre-launch activities
“Our third quarter was marked by strong commercial performance, meaningful pipeline progress and important regulatory achievements. Net sales growth was strong in both the U.S. and internationally, creating a durable core business beyond Jakafi.”
Incyte CEO, on the earnings call
What Is Incyte's Outlook?
Incyte raised its full-year 2026 guidance on continued strong performance across the portfolio: - Total net sales: $5,210–$5,300 million (previously $5,130–$5,260 million). - Opzelura net sales: $1,100–$1,120 million (previously $1,050–$1,100 million), including a one-time $246 million CMS-related benefit. - Hematology and Oncology net sales: $890–$910 million (previously $860–$890 million). It reaffirmed the remaining guidance: - Jakafi net sales: $3,220–$3,270 million. - Total GAAP R&D and SG&A expenses: $4,915–$4,995 million, including the $1.23 billion Vega IPR&D charge. - Total non-GAAP R&D and SG&A expenses: $4,625–$4,695 million. Near-term catalysts include: - Q4 2026 Phase 3 data for povorcitinib in prurigo nodularis and ruxolitinib cream in HS. - An EC decision on povorcitinib in HS. - Potential Q1 2027 U.S. approvals and launches for povorcitinib in HS and Monjuvi in newly diagnosed DLBCL. Management expects multiple paths to growth beyond 2029.
INCY YoY Financials
| Metric | Q3 2026 | Q3 2025 | Year over year |
|---|---|---|---|
| Revenue | $1.6B | $1.4B | +14.0% |
INCY Revenue by Segment
When Does Incyte Report Next?
Figures from SEC filings and company reports. Not investment advice.